|

DZD8586 Clinical Trials

3 actively recruiting trials

▼ -1 trial since June 2026

Also known as: Birelentinib

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • Dizal Pharmaceuticals3

Indications

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma3
  • Cancer3

Other3 trials

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Phase 2
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Phase 3
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.